Weiss, Anna http://orcid.org/0000-0001-5671-959X
King, Claire
Vincuilla, Julie
Parker, Tonia
Portnow, Leah
Nakhlis, Faina
Dominici, Laura
Mittendorf, Elizabeth A.
King, Tari A.
Funding for this research was provided by:
Division of Cancer Epidemiology and Genetics, National Cancer Institute (1P50CA168504)
Rob and Karen Hale Distinguished Chair in Surgical Oncology
Article History
Received: 21 April 2022
Accepted: 4 July 2022
First Online: 28 July 2022
Declarations
:
: AW reports institutional research funding from Myriad Laboratories Inc. EAM: reports clinical trial funding from Roche/Genentech (via SU2C grant) and Gilead; compensated advisory board service for, and consulting fees from, Roche/Genentech, Merck, and Exact Sciences; compensated advisory board service for AstraZeneca; honoraria from Physicians’ Education Resource; and uncompensated service on the Board of Directors for the American Society of Clinical Oncology, the steering committees of Roche/Genentech, Bristol-Myers Squibb, and Eli Lilly, and uncompensated service as a Scientific Advisor for Susan G. Komen for the Cure Foundation. TAK reports Speakers honoraria and an advisory board role for Exact Sciences; Faculty, PrecisCA cancer information service; and is on the global advisory board of Besins Healthcare.
: Institutional Quality Improvement approval was obtained prior to data review and manuscript preparation.
: The need for informed consent was waived for this study; this was reviewed and approved as a quality improvement project by our institution.